12:00 AM
Sep 22, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Meningitis B vaccine: Phase II data

In a single-blind, U.K. Phase II trial in 60 healthy infants 6-8 months old, MenB vaccine produced protective immune responses against the vaccine's 3 major antigens in 100%, 100% and 96%, respectively, after the third dose. Only...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >